期刊
JOURNAL OF NEUROLOGY
卷 263, 期 3, 页码 575-582出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s00415-015-7991-1
关键词
Neuromyelitis optica spectrum disorder; Devic's disease; Glatiramer acetate; Aquaporin-4 antibody; Optic neuritis; Myelitis
资金
- International Headache Society
- German Research Foundation
- Biogen Idec
- Bayer
- Teva
- Merck
- Novartis
- Genzyme
- Bayer Healthcare
- Chugai
- Merck Serono
- German Science Foundation (DFG)
- Federal Ministry of Education and Research (BMBF, EDEN/EU-FP7)
- Bayer-Schering AG
- German Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis)
- Novartis Pharmaceuticals
- European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
- Sanofi Company
- Guthy Jackson Charitable Foundation
- MERCUR Foundation
Glatiramer acetate (GA) is an approved therapy for relapsing-remitting multiple sclerosis, but its efficacy for the prevention of attacks in neuromyelitis optica spectrum disorder (NMOSD) remains unknown. We did a multicenter retrospective analysis of GA-treated patients with NMOSD, identified through a national registry. Annualized relapse rate and expanded disability status scale (EDSS) were the main outcome measures. We identified 23 GA-treated patients (21 female, 16 aquaporin-4 antibody-positive). GA was given for < 6 months in seven patients; reasons for stopping were relapses (n = 3), confirmation of NMOSD (n = 2) and side effects (n = 2). Of 16 patients treated a parts per thousand yen6 months with GA (15 female, 11 aquaporin-4 antibody-positive), 14 experienced at least one relapse. There was no reduction in the mean annualized relapse rate in the total group (1.9 +/- A 1.1 before vs. 1.8 +/- A 1.4 during GA therapy), as well as in those patients who were aquaporin-4 antibody-positive, or had a history of prior immunotherapy or not. The median EDSS increased (2.5 start vs. 3.5 finish of GA, P < 0.05). GA therapy was discontinued in 15/16 patients; reasons were therapeutic inefficacy in 13 and post-injection skin reactions in two patients. We conclude that GA is not beneficial for preventing attacks in most patients with NMOSD, particularly in aquaporin-4 antibody-positive cases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据